Met as a therapeutic target in HCC: Facts and hopes

Silvia Giordano, Amedeo Columbano

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and its burden is expected to increase further in the next years. In spite of the advances of classical therapies, such as surgery, transplantation, use of radiofrequency and transarterial embolization, the prognosis of this neoplasm has not considerably improved over the past few years. The advent of targeted therapies and the approval of the systemic treatment of advanced HCC with the kinase inhibitor sorafenib have provided some hope for the future. Even if the molecular mechanisms responsible for the onset and progression of HCC are still largely unknown, new therapeutic targets have recently come to the spotlight. One of these targets is the tyrosine kinase receptor for the Hepatocyte Growth Factor, encoded by the MET gene, known to promote tumor growth and metastasis in many human organs. In this review we will summarize the contrasting results obtained in vitro (in HCC cell lines) and in animal experimental models and we will also try to analyze the reasons for the opposite findings, suggesting that the HGF/MET axis can have either a promoting or a suppressive role in the development of HCC. We will also reconsider the evidence of activation of this pathway in human HCCs and discuss the results of the clinical trials performed with MET inhibitors. The final purpose is to better clarify which can be the role of MET as a therapeutic target in HCC.

Original languageEnglish
Pages (from-to)442-452
Number of pages11
JournalJournal of Hepatology
Volume60
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Neoplasms
Hepatocyte Growth Factor
Receptor Protein-Tyrosine Kinases
Phosphotransferases
Animal Models
Transplantation
Clinical Trials
Neoplasm Metastasis
Cell Line
Growth
Genes

Keywords

  • Clinical trials
  • Hepatocellular carcinoma
  • HGF
  • MET
  • Targeted therapies

ASJC Scopus subject areas

  • Hepatology

Cite this

Met as a therapeutic target in HCC : Facts and hopes. / Giordano, Silvia; Columbano, Amedeo.

In: Journal of Hepatology, Vol. 60, No. 2, 02.2014, p. 442-452.

Research output: Contribution to journalArticle

Giordano, Silvia ; Columbano, Amedeo. / Met as a therapeutic target in HCC : Facts and hopes. In: Journal of Hepatology. 2014 ; Vol. 60, No. 2. pp. 442-452.
@article{dc1a75e8e40b45aebd59604638e45be6,
title = "Met as a therapeutic target in HCC: Facts and hopes",
abstract = "Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and its burden is expected to increase further in the next years. In spite of the advances of classical therapies, such as surgery, transplantation, use of radiofrequency and transarterial embolization, the prognosis of this neoplasm has not considerably improved over the past few years. The advent of targeted therapies and the approval of the systemic treatment of advanced HCC with the kinase inhibitor sorafenib have provided some hope for the future. Even if the molecular mechanisms responsible for the onset and progression of HCC are still largely unknown, new therapeutic targets have recently come to the spotlight. One of these targets is the tyrosine kinase receptor for the Hepatocyte Growth Factor, encoded by the MET gene, known to promote tumor growth and metastasis in many human organs. In this review we will summarize the contrasting results obtained in vitro (in HCC cell lines) and in animal experimental models and we will also try to analyze the reasons for the opposite findings, suggesting that the HGF/MET axis can have either a promoting or a suppressive role in the development of HCC. We will also reconsider the evidence of activation of this pathway in human HCCs and discuss the results of the clinical trials performed with MET inhibitors. The final purpose is to better clarify which can be the role of MET as a therapeutic target in HCC.",
keywords = "Clinical trials, Hepatocellular carcinoma, HGF, MET, Targeted therapies",
author = "Silvia Giordano and Amedeo Columbano",
year = "2014",
month = "2",
doi = "10.1016/j.jhep.2013.09.009",
language = "English",
volume = "60",
pages = "442--452",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Met as a therapeutic target in HCC

T2 - Facts and hopes

AU - Giordano, Silvia

AU - Columbano, Amedeo

PY - 2014/2

Y1 - 2014/2

N2 - Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and its burden is expected to increase further in the next years. In spite of the advances of classical therapies, such as surgery, transplantation, use of radiofrequency and transarterial embolization, the prognosis of this neoplasm has not considerably improved over the past few years. The advent of targeted therapies and the approval of the systemic treatment of advanced HCC with the kinase inhibitor sorafenib have provided some hope for the future. Even if the molecular mechanisms responsible for the onset and progression of HCC are still largely unknown, new therapeutic targets have recently come to the spotlight. One of these targets is the tyrosine kinase receptor for the Hepatocyte Growth Factor, encoded by the MET gene, known to promote tumor growth and metastasis in many human organs. In this review we will summarize the contrasting results obtained in vitro (in HCC cell lines) and in animal experimental models and we will also try to analyze the reasons for the opposite findings, suggesting that the HGF/MET axis can have either a promoting or a suppressive role in the development of HCC. We will also reconsider the evidence of activation of this pathway in human HCCs and discuss the results of the clinical trials performed with MET inhibitors. The final purpose is to better clarify which can be the role of MET as a therapeutic target in HCC.

AB - Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and its burden is expected to increase further in the next years. In spite of the advances of classical therapies, such as surgery, transplantation, use of radiofrequency and transarterial embolization, the prognosis of this neoplasm has not considerably improved over the past few years. The advent of targeted therapies and the approval of the systemic treatment of advanced HCC with the kinase inhibitor sorafenib have provided some hope for the future. Even if the molecular mechanisms responsible for the onset and progression of HCC are still largely unknown, new therapeutic targets have recently come to the spotlight. One of these targets is the tyrosine kinase receptor for the Hepatocyte Growth Factor, encoded by the MET gene, known to promote tumor growth and metastasis in many human organs. In this review we will summarize the contrasting results obtained in vitro (in HCC cell lines) and in animal experimental models and we will also try to analyze the reasons for the opposite findings, suggesting that the HGF/MET axis can have either a promoting or a suppressive role in the development of HCC. We will also reconsider the evidence of activation of this pathway in human HCCs and discuss the results of the clinical trials performed with MET inhibitors. The final purpose is to better clarify which can be the role of MET as a therapeutic target in HCC.

KW - Clinical trials

KW - Hepatocellular carcinoma

KW - HGF

KW - MET

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84892549017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892549017&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2013.09.009

DO - 10.1016/j.jhep.2013.09.009

M3 - Article

C2 - 24045150

AN - SCOPUS:84892549017

VL - 60

SP - 442

EP - 452

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -